About |  Partners |  Affiliations |  Acknowledgements

About Interactive Biosoftware

The company was founded in 2007 by a group of medical and computer scientists. It focuses on practical software applications for healthcare and life sciences, mainly in the molecular biology area.

Interactive Biosoftware is based in the beautiful city of Rouen, the historical capital of Normandy, France, in the Seine Biopolis biomedical dedicated entreprise area.

The name of the company is inspired by the idea that interactions between humans and computers give rise to powerful effects (see Peter Wegner's paper Why Interaction Is More Powerful Than Algorithms).

The company is closely connected to the internationally recognized Rouen University Hospital Genetics Department and to the Molecular Genetics research group of Rouen University (INSERM U614).

Interactive Biosoftware also benefits from rich interactions with a number of its client institutions.

Partners

	The U614 Inserm research unit in Rouen University is specialized in molecular genetics of cancer and neuropsychiatric diseases. Its research topics encompass: Development of new methods for the detection of genetic alterations, Alteration of gene dosage, RNA diseases, Genetics of colorectal cancer and Li-Fraumeni syndrome, Targeted therapies in colorectal cancer, Genetics and physiopathology of Alzheimer and dementia and Genetic bases of psychoses.
	BIOBASE offers a complete range of high-quality databases and analysis tools for the life science industry. The Human Gene Mutation Database, available in Alamut to HGMD® Professional suscribers, is the world's premier database for inheritable disease-causing mutations and disease-associated SNPs in human. Annotations from Genome Trax™, a database solution for Next Generation Sequencing data analysis, are also available in Alamut.
	Fluigent conceives, develops, manufactures and markets innovative instruments, diagnostic kits and building blocks for Life Science and Microfluidics, such as diagnosis, bioanalytical applications and nanotechnologies. Fluigent markets innovative matrices for capillary electrophoresis detection of unknown mutation.